Search

https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf


At Matrivax, we are developing effective vaccines to address three of these concerning threats:


Urgent threat – C. difficile

Serious threat – S. pneumoniae, drug resistant

Serious threat – S. Typhi, drug resistant





22 views0 comments
  • Nicole Ruggiero

Dr. Killeen (CEO) will be presenting at Vaccines Research And Development, November 19, 2019, at the Crowne Plaza Boston.


12:10-12:35 Prophylactic and therapeutic vaccine approach targeting C. difficile infection and relapse. Kevin Killeen, Chief Scientific Officer, Matrivax R&D Corp



39 views0 comments